New cancer clinical trial: A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors

Published on: November 30, 2018 at 10:30PM

• Tweet
• Share
• Share
• Share
• Share